Development of Gene Editing Strategies for Human β-Globin (HBB) Gene Mutations
Batuhan Mert KalkaniD, Ezgi Yağmur KalaiD, Melek YüceiD, Medine Karadag AlpaslaniD, Fatih KocabaşiD
Abstract
Recent developments in gene editing technology have enabled scientists to modify DNA sequence by using engineered endonucleases. These gene editing tools are promising candidates for clinical applications, especially for treatment of inherited disorders like sickle cell disease (SCD). SCD is caused by a point mutation in human {beta}-globin gene (HBB). Clinical strategies have demonstrated substantial success, however there is not any permanent cure for SCD available. CRISPR/Cas9 platform uses a single endonuclease and a single guide RNA (gRNA) to induce sequence-specific DNA double strand break (DSB). When this accompanies a repair template, it allows repairing the mutated gene. In this study, it was aimed to target HBB gene via CRISPR/Cas9 genome editing tool to introduce nucleotide alterations for efficient genome editing and correction of point mutations causing SCD in human cell line, by Homology Directed Repair (HDR). We have achieved to induce target specific nucleotide changes on HBB gene in the locus of mutation causing SCD. The effect of on-target activity of bone fide standard gRNA and newly developed longer gRNA were examined. It is observed that longer gRNA has higher affinity to target DNA while having the same performance for targeting and Cas9 induced DSBs. HDR mechanism was triggered by co-delivery of donor DNA repair templates in circular plasmid form. In conclusion, we have suggested methodological pipeline for efficient targeting with higher affinity to target DNA and generating desired modifications on HBB gene. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/908319v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@18f810org.highwire.dtl.DTLVardef@1461dfcorg.highwire.dtl.DTLVardef@5a9546org.highwire.dtl.DTLVardef@fe5815_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG HighlightsO_LIHBB gene were targeted by spCas9 in close proximity to the SCD mutation C_LIO_LILong gRNA, which is designed to target SCD mutation, is sickle cell disease specific and exhibits indistinguishable level of cleavage activity on target locus. C_LIO_LIFunctional HBB HDR repair templates with 1 Kb and 2 Kb size were generated to cover all known mutations in the HBB gene. C_LIO_LIReplacement of PAM sequence in HDR template with HindIII recognition sequence allowed a quick assessment of the HDR efficiency. C_LIO_LIHDR template: Cas9-GFP vector 2:1 ratio yielded the highest HDR events/GFP+ cells. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 0.81
- Field percentile
- top 34%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein Complex
Mark A. DeWitt, Wendy Magis, … Jacob E. Corn·bioRxiv·Jan 15, 2016
- Precise modelling and correction of a spectrum of β-thalassemic mutations in human erythroid cells by base editors
K. Manjunatha Prasad, Nivedhitha Devaraju, … Kumarasamypet Murugesan Mohankumar·bioRxiv·Jun 1, 2022
- Evaluation of persistence and fate of ex vivo edited-HSC modified with donor template and Its role in correcting Sickle Cell Disease
Sowmya Pattabhi, Samantha N. Lotti, … David J. Rawlings·bioRxiv·Jun 30, 2021
- Efficient repair of human homozygous genetic mutation by CRISPR/Cas9 mediated interlocus gene conversion
Fei Yang, Jingtao Pang, … Yuxuan Wu·bioRxiv·Sep 5, 2022
- High-level correction of the sickle mutation amplified in vivo during erythroid differentiation
Wendy Magis, Mark A. DeWitt, … David I. K. Martin·bioRxiv·Jan 8, 2019
- Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease
Varun Katta, Kiera O’Keefe, … Shengdar Q. Tsai·Molecular TherapyPeer-reviewed·Jul 30, 2024